

# Spreekers

---

## **Daan Crommelin**

Prof. Daan Crommelin is emeritus-professor at the Department of Pharmaceutics at Utrecht University. Until December 2011 he was scientific director of the Dutch Top Institute Pharma in Leiden. He is adjunct professor at the Department of Pharmaceutics and Pharmaceutical Chemistry at the University of Utah. Crommelin is co-founder of OctoPlus, a Leiden based company specialized in the development of pharmaceutical product formulations and advanced drug delivery systems. He published extensively and is on the editorial board of 10 peer reviewed journals in the pharmaceutical sciences. He also advises venture capital groups. He chaired the Board of Pharmaceutical Sciences of the International Pharmaceutical Federation (F.I.P.), was chair of the organizing committee of the Pharmaceutical Sciences World Conference 2007 in Amsterdam. He is past president of the European Federation of Pharmaceutical Sciences (EUFEPS) and past vice-chair of the scientific advisory board of the European Innovative Medicines Initiative (IMI)



## **Mirjam Mol-Arts**

Mirjam Mol-Arts is sinds 1 oktober 2014 directeur van het Pivot Park en Pivot Park Screening Centre. Zij richt zich volledig op het verder uitbreiden van het Pivot Park, het bouwen aan de community en het verder verbeteren van de infrastructuur. Uiteraard naast de dagelijkse leiding over het Pivot Park en het Pivot Park Screening Centre. Mirjam is cum laude afgestudeerd in de geneeskunde aan de Universiteit Utrecht. Zij heeft een gedegen medisch wetenschappelijke achtergrond en ruime ervaring in verschillende bedrijven en organisaties gelieerd aan life sciences en gezondheid. Sinds 2011 maakte zij deel uit van het Nederlandse management van MSD en was bestuursvoorzitter van het lokale management van MSD in Oss. Ze was nauw betrokken bij de oprichting van Pivot Park en maakte deel uit van de Task Force Life Sciences Oss. Ook heeft zij een uitgebreid nationaal en internationaal netwerk in de Lifes Sciences en Health wereld.



## **Steven van Helden**

Steven van Helden studied chemistry at Utrecht University and, after obtaining his Ph.D. , worked in various roles in pharmaceutical industry for 20 years. Since 2003 he has been responsible for High Throughput Screening (HTS) operations and strategy at Organon/MSD. After the closure of those research facilities he developed a business plan for continuation of the screening activities in Oss, The Netherlands. This led to the formation of the Pivot Park Screening Centre (PPSC) and a central role of this company in the European Lead Factory. Steven is now responsible for business development at PPSC.



### **Frank Leemhuis**

Dr. Frank Leemhuis is co-founder and managing director of Mercachem. He studied chemistry at the University of Nijmegen and received his PhD degree in 1994 on the total synthesis of macrocyclic ring lactones. He worked from 1993 to 1997 with Specs in The Hague as Manager Compound Acquisition. In 1997, he co-founded Mercachem together with Dr. Eelco Ebbers. Mercachem is a privately owned contract research organization located in Nijmegen and Prague, offering innovative chemistry, medicinal chemistry, early process research and GMP manufacturing to accelerate the drug discovery and development process in a flexible and cost-effective way. In his career, Frank has gained broad experience with the start-up, growth and management of a medium sized organization and developed further skills in business development, project- and account management. In 2010 he was elected as "Entrepreneur of the year" of the City of Nijmegen. In 2012 he became a member of the Board of Directors of Top Institute Pharma (now Lygature) in The Netherlands and is also member of the Advisory Board of the EFMC..



### **Kees Bol**

Senior Consultant Drug Development. Kees Bol, PhD, is working as senior consultant for international biotech and pharmaceutical companies (small and large molecules). In addition he's responsible for the daily management of the administrative office in Singapore. In the 14 year period with Kinesis he fulfilled several managerial functions in Early Clinical Development, Pharmacokinetics and Project Management. For several start-up companies he lead (virtual) compound development teams carrying compounds from candidate selection through clinical proof of concept. Prior to joining Kinesis he worked for 5 years as PK/PD expert at Janssen Pharmaceutica (a Johnson & Johnson company) in Belgium. He was member of a number of global drug development teams in oncology. He received his Ph.D. degree in pharmacology from a collaborative project between the Universities of Leiden, the Netherlands and Stanford, USA. He is (co)-author of more than 10 scientific articles in peer reviewed journals.



### **Jan Van der Schueren**

Jan Van der Schueren is Discovery Site Head at Galapagos. In this role, he contributes to Galapagos' drug discovery projects in the fields of cystic fibrosis, inflammation, metabolic diseases, anti-infectives and fibrosis, and more specifically with in vitro pharmacology and medicinal chemistry activities that are executed at the Research site in Mechelen, Belgium. Jan obtained a PhD in Applied Biological Sciences from the University of Leuven, Belgium. After a post-doc at the Laboratory of Gene Technology, University of Leuven, he joined Galapagos in 1999. He assumed a diverse set of responsibilities, going from leading the Discovery Informatics team consisting of software developers and bio- and chemo-informatics scientists that support the company's target and drug discovery programs, over drug discovery project management in the osteoarthritis field, up to program management with setting up the drug discovery for the cystic fibrosis therapeutic area. In recent years, Jan also scouted for new technologies that could further enrich the drug discovery capabilities at Galapagos.



**Allard Kaptein**

Allard Kaptein, PhD (Executive Vice President, Discovery at Acerta Pharma). Allard is founder of Acerta Pharma and as Executive Vice President Discovery responsible for new targets/programs for the company. In addition, to heading Discovery activities, he is responsible for the Translational Science directed towards autoimmune/inflammatory indications”at Acerta Pharma. Allard received his PhD in Biopharmaceutical Sciences at the Gaubius Institute TNO in Leiden, after which he worked in different positions in the pharmaceutical industry at Glaxo/GlaxoWellcome/GSK in France and the UK and later at Organon/ScheringPlough/MSD in the Netherlands. Allard is Cell Biologist by training with over 20 years experience in the pharmaceutical industry in Autoimmune Diseases, Oncology and Cardiovascular Diseases, with focus on translational biology in drug discovery and development.

**Walter Westerink,**

Walter is Senior scientist and Study Director Discovery & Environmental Sciences at WIL Research. He has more than 4 years experience in the Contract Research Industry at WIL Research and 14 years of drug development experience in pharmaceutical industry at NV Organon within a broad range of therapeutic areas (i.e. thrombosis, atherosclerosis, women’s health, metabolic diseases, hormone dependent cancers, and inflammatory diseases). In September 2014 appointed as member of the Scientific Advisory Board of WIL Research.

Specialties: Pre-clinical drug development, in vitro toxicology, genotoxicity, safety pharmacology, assay development and optimization, lab automation, medium throughput screening, GLP, 21 CFR part 11 validations, REACH.

**Henk Viëtor,**

Dr. Henk Viëtor is founder and managing director of Drug Discovery Factory (DDF). Henk has graduated from medical school at the University of Amsterdam in 1992. After completing his training as a MD, he specialized in Immunology and Transfusion Medicine at the University Medical Centre in Leiden. He completed his thesis on the development of the fetal immune system and then specialized in Clinical Genetics at the University Medical Centre, St Radboud in Nijmegen. He was editor of the proceedings for the society of experimental Biology and medicine from 1997 till 2003. He is a speaker on many national and international conferences and is actively involved in several grant submission committees including Casimir (exchange of people between industry and academia), Telethon and the Dutch National Genomics Initiative (NGI), Meer Kennis met Minder Dieren (MKMD). He published numerous articles in first-tier scientific journals, filed several patents. Henk Viëtor is an active entrepreneur in the life sciences industry and has (co-)founded several biotechnology companies, including Drug Discovery Factory, Multigen, Skyline Diagnostics, DC4U, MyLife, Immunafect and Recharge. From 2005-2012 he was CEO of Skyline Diagnostics.



### **Stefan Braam**

Stefan Braam is the CEO and Co-founder of Pluriomics. Stefan Braam brings over a decade of experience in stem cell research and product development. Under his leadership the company grew from idea to international commercial organization. As key inventor of the underlying Pluriomics technologies and Chief Scientific Officer of the company he has been instrumental in the establishment and initial development of the company. Earlier in his career, Stefan obtained a PhD and MSc (both cum laude) in stem cell biology under supervision of Prof. Dr Mummery and obtained international experience in laboratoria in the UK and Australia.



### **Jacques van den Broek**

Jacques van den Broek was appointed Head of Screening at PPSC in December 2012. He has a background in pharmaceutical research in fields ranging from lab automation and IT, to biology and screening. He studied histology, tissue culturing and physiology, and pharmacology at the Dr. Ir W.L. Ghijzen Institute, Utrecht (1978-1982). He has also followed a number of biology and IT courses at the Open University. He started at Organon in 1982 in the fields of electron microscopy and image analysis. In 1995 he became Research Technology Coordinator for Organon (and its successors) and played a key role in setting up four generations of screening systems, compound logistics and data processing infrastructures. In 2012 he started the laboratory automation company LAC4LS.



### **Gerjan Kemperman**

Chief Executive Officer and Founder, ChemConnection BV  
Gerjan Kemperman is an entrepreneur pur sang who holds a PhD from the Radboud University in the Netherlands. Starting his pharmaceutical industry career as a development scientist at Organon, he quickly became responsible for process R&D and cGMP API delivery in various leadership positions and remained at Merck Sharp & Dohme, Schering-Plough, and Organon for over 11 years. In 2012, Gerjan co-founded ChemConnection and he has operated as CEO since then.



### **Giel Hendriks,**

Giel Hendriks studied Biology at the Utrecht University in the Netherlands, with a masters in Molecular Biology. He did his PhD at the department of Cell biology in the University Medical Center Utrecht where he studies the biosynthesis and intracellular trafficking of Aquaporin water channels in kidney cells. After his PhD Giel worked as a Post-doctoral fellow at the Department of Toxicogenetics in the Leiden University where he studied the impact of gene transcription on DNA damage-induced mutagenesis. After this fundamental scientific projects Giel consciously made a switch to a more applied project. With Dr. Harry Vrieling at the department of the Leiden University Medical Center, he used their combined expertise on the cellular DNA damage response to create in vitro reporter system for the detection of genotoxicity. During the last five years they have developed and validated the ToxTracker assay, a stem-cell based reporter system do rapidly detect various cancer-associated biological reactivities of chemicals. Giel recently founded the company Toxys to bring the ToxTracker assay to the market. Currently he is working as managing director of Toxys, offering services for chemical safety and carcinogenicity testing.

